## Edgar Filing: MERRIMACK PHARMACEUTICALS INC - Form 4

MERRIMA Form 4 February 10	CK PHARMACE	EUTICAL	S INC							
FORM	ЛЛ	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(b) of the Investment Company Act of 1940							PPROVAL 3235-0287	
Check t if no lor subject Section Form 4 Form 5 obligati may cor <i>See</i> Inst 1(b).	nger to 16. or Filed put ons stinue.								Number: January 31 Expires: 2005 Estimated average burden hours per response 0.5	
(Print or Type	Responses)									
1. Name and Al-Wakeel	2. Issuer Name <b>and</b> Ticker or Trading Symbol MERRIMACK PHARMACEUTICALS INC [MACK]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title 0ther (specify below) CFO and Head of Corp Dev					
(Last) C/O MERI PHARMA KENDALI B7201	3. Date of Earliest Transaction (Month/Day/Year) 02/08/2016									
	(Street)	(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person		
CAMBRIE	OGE, MA 02139							More than One R		
(City)	(State)	(Zip)	Tat	ole I - Non-J	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8) Code V	4. Securit onAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Re	port on a separate line	e for each cl	ass of sec	urities bene	Perso	ons who res	or indirectly. Spond to the collection and the coll		SEC 1474 (9-02)	

information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

## CAMBRIDGE, MA 02139 Signatures /s/ Jeffrey A. Munsie, attorney-in-fact 02/10/2016 \*\*Signature of Reporting Person Date **Explanation of Responses:** If the form is filed by more than one reporting person, see Instruction 4(b)(v). \*\*

## Edgar Filing: MERRIMACK PHARMACEUTICALS INC - Form 4

1. Title of 3. Transaction Date 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount of 2 4. Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative **Expiration Date Underlying Securities** (Month/Day/Year) (Instr. 3 and 4) Security or Exercise any Code Securities Price of (Month/Day/Year) (Instr. 8) Acquired (A) or (Instr. 3) Derivative Disposed of (D) Security (Instr. 3, 4, and 5) Amount or Date Expiration Title Number of Date Exercisable (D) Code V (A) Shares Stock Option Common (1) 02/07/2026 \$ 5.42 02/08/2016 105,000 105,000 Α Stock (right to buy)

Relationships

CFO and Head of Corp Dev

Officer

## **Reporting Owners**

Al-Wakeel Yasir B.

**Reporting Owner Name / Address** 

C/O MERRIMACK PHARMACEUTICALS, INC.

ONE KENDALL SQUARE, SUITE B7201

Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This option vests as to 1/12th of the total number of shares on 5/8/16 and an additional 1/12th of the total number of shares at the end of (1)each successive three month period thereafter until 2/8/19.

Director

10% Owner

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Other